Mirum Pharmaceuticals Inc (MIRM) reported better-than-expected financial results for the third quarter of fiscal 2025. The company achieved earnings per share (EPS) of $0.05, significantly surpassing Wall Street's consensus estimate of $-0.17 by $0.22. Revenue for the quarter matched expectations at $0.1 billion.
The announcement highlights the company's solid operational performance, which may reflect stronger business fundamentals. Mirum Pharmaceuticals, based in Foster City, California, is focused on developing treatments for rare diseases affecting both children and adults. The firm has three key products: LIVMARLI (maralixibat), Cholbam (cholic acid), and Chenodal (chenodiol).
The company will host an earnings conference call after market close to discuss these results and provide further insights into its business performance.
Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook. Upcoming earnings are scheduled for May 4, 2026, with an estimated EPS of $-0.0279 and revenue of $0.1 billion, followed by another report on August 3, 2026, with an EPS estimate of $-0.0369 and revenue also projected at $0.1 billion.